- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 26.02. | Bicara Therapeutics closes $172.5 million stock offering | 1 | Investing.com | ||
| 26.02. | Bicara Therapeutics schließt Aktienplatzierung über 172,5 Millionen US-Dollar ab | 3 | Investing.com Deutsch | ||
| 26.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 1 | GlobeNewswire (USA) | ||
| 25.02. | Bicara Therapeutics prices $150 million stock offering at $16 | 2 | Investing.com | ||
| 25.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 24.02. | Bicara Therapeutics kündigt Aktienemission im Wert von 150 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.02. | Bicara Therapeutics launches $150 million stock offering | 2 | Investing.com | ||
| 24.02. | Bicara Therapeutics launches $150M public stock offering | 1 | Seeking Alpha | ||
| 24.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 23.02. | Bicara Therapeutics stock rating reaffirmed by Citizens at Market Outperform | 2 | Investing.com | ||
| 20.02. | Bicara Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.02. | Bicara Therapeutics stock rating maintained at Market Outperform by Citizens | 1 | Investing.com | ||
| 19.02. | Bicara Therapeutics Inc.: Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen | 1 | GlobeNewswire (USA) | ||
| 19.02. | Bicara Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.01. | Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating | 1 | Investing.com | ||
| 29.01. | Bicara Therapeutics: Citizens startet Coverage mit "Market Outperform" und hohem Kursziel | 2 | Investing.com Deutsch | ||
| 15.01. | Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress | 1 | Investing.com | ||
| 12.01. | Bicara legt optimale Dosis für zulassungsrelevante Studie zu Kopf-Hals-Krebs fest | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 15,120 | 0,00 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| DYNE THERAPEUTICS | 15,230 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,545 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| QIAGEN | 39,760 | -2,73 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,15 | -4,39 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| ARCELLX | 114,26 | 0,00 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 27,410 | 0,00 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| UPSTREAM BIO | 7,800 | 0,00 % | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,070 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,370 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| DISC MEDICINE | 61,04 | -6,45 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial... ► Artikel lesen | |
| NUVALENT | 102,71 | +1,40 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 72,25 | 0,00 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| VERA THERAPEUTICS | 39,650 | 0,00 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| MINERALYS THERAPEUTICS | 28,800 | -1,87 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen |
Das Unternehmen BICARA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 18,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.